Motif Neurotech – a neurotechnology company developing minimally-invasive bioelectronics for mental health – recently announced an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital, individual investor Max Hodak and existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures and Capital Factory.
The proceeds from the Series A financing will be used to advance the development of Motif’s lead product DOT microstimulator, a miniature brain pacemaker designed to precisely stimulate the brain to restore healthy circuit activity to treat mental health disorders. And the initial indication Motif is pursuing for the device is treatment-resistant depression (TRD), a form of major depressive disorder (MDD) that is resistant to anti-depressant medications.
Amy Kruse, chief investment officer of Satori Neuro and Tom Shehab will join the Board of Directors at Motif Neurotech, along with Anthony Arnold, and Jacob Robinson.
KEY QUOTES:
“Minimally-invasive bioelectronics are the future of mental health treatment. 30% of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible. The DOT microstimulator is a wireless, battery-free device designed to be implanted in a 20-minute outpatient procedure with the capability for at-home therapy. This round of financing will allow us to bring this technology into a clinical study for patients with TRD.”
– Jacob Robinson, CEO & Founder, Motif Neurotech
“We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD. We are proud to lead this round of financing with this world-class team.”
– Tom Shehab, managing partner of Arboretum Ventures
